New triple therapy shows promise for tough liver cancers
NCT ID NCT06349317
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new approach for people with liver cancer that has spread to the portal vein (the main blood vessel to the liver). Participants will receive radiation therapy before surgery, along with two drugs (camrelizumab and apatinib) before and after surgery. The goal is to see if this combination can prevent the cancer from coming back. About 33 adults with this specific type of liver cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mengchao Hepatobiliary Hospital, Fujian Medical University
RECRUITINGFuzhou, Fujian, China
Contact